Saito K, Fujigaki S, Heyes M P, Shibata K, Takemura M, Fujii H, Wada H, Noma A, Seishima M
Department of Laboratory Medicine, Gifu University School of Medicine, Gifu 500-8705, Japan.
Am J Physiol Renal Physiol. 2000 Sep;279(3):F565-72. doi: 10.1152/ajprenal.2000.279.3.F565.
Marked increases in metabolites of the L-tryptophan-kynurenine pathway, L-kynurenine and quinolinic acid (Quin), were observed in serum and cerebrospinal fluid (CSF) of both the rat and human with renal insufficiency. The mechanisms responsible for their accumulation after renal insufficiency were investigated. In patients with chronic renal insufficiency, elevated levels of serum L-kynurenine and Quin were reduced by hemodialysis. In renal-insufficient rats, Quin and L-kynurenine levels in serum, brain, and CSF were also increased parallel to the severity of renal insufficiency. Urinary excretion of Quin (3.5-fold) and L-kynurenine (2.8-fold) was also increased. Liver L-tryptophan 2,3-dioxygenase activity (TDO), a rate-limiting enzyme of the kynurenine pathway, was increased in proportion to blood urea nitrogen and creatinine levels. Kynurenine 3-hydroxylase and quinolinic acid phosphoribosyltransferase were unchanged, but the activities of kynureninase, 3-hydroxyanthranilate dioxygenase, and aminocarboxymuconate-semialdehyde decarboxylase (ACMSDase) were significantly decreased. Systemic administrations of pyrazinamide (ACMSDase inhibitor) increased serum Quin concentrations in control rats, demonstrating that changes in body ACMSDase activities in response to renal insufficiency are important factors for the determination of serum Quin concentrations. We hypothesize the following ideas: that increased serum L-kynurenine concentrations are mainly due to the increased TDO and decreased kynureninase activities in the liver and increased serum Quin concentrations are due to the decreased ACMSDase activities in the body after renal insufficiency. The accumulation of CSF L-kynurenine is caused by the entry of increased serum L-kynurenine, and the accumulation of CSF Quin is secondary to Quin from plasma and/or Quin precursor into the brain.
在大鼠和人类肾功能不全患者的血清和脑脊液(CSF)中,均观察到L-色氨酸-犬尿氨酸途径的代谢产物L-犬尿氨酸和喹啉酸(Quin)显著增加。对肾功能不全后其蓄积的机制进行了研究。在慢性肾功能不全患者中,血液透析可降低血清L-犬尿氨酸和Quin的升高水平。在肾功能不全的大鼠中,血清、脑和脑脊液中的Quin和L-犬尿氨酸水平也随着肾功能不全的严重程度而平行升高。Quin(3.5倍)和L-犬尿氨酸(2.8倍)的尿排泄量也增加。肝脏L-色氨酸2,3-双加氧酶活性(TDO)是犬尿氨酸途径的限速酶,其活性与血尿素氮和肌酐水平成比例增加。犬尿氨酸3-羟化酶和喹啉酸磷酸核糖基转移酶未发生变化,但犬尿氨酸酶、3-羟基邻氨基苯甲酸双加氧酶和氨基羧基粘康酸半醛脱羧酶(ACMSDase)的活性显著降低。对对照大鼠全身给予吡嗪酰胺(ACMSDase抑制剂)可增加血清Quin浓度,表明机体ACMSDase活性响应肾功能不全的变化是决定血清Quin浓度的重要因素。我们提出以下假说:血清L-犬尿氨酸浓度升高主要是由于肝脏中TDO增加和犬尿氨酸酶活性降低,而血清Quin浓度升高是由于肾功能不全后机体ACMSDase活性降低。脑脊液L-犬尿氨酸的蓄积是由于血清L-犬尿氨酸增加的进入所致,而脑脊液Quin的蓄积继发于血浆中的Quin和/或Quin前体进入脑内。